The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis.
Ibrahim AS, Spellberg BJ, Avanesian V, Fu Y, Edwards JE Jr.
Ibrahim AS, et al.
Infect Immun. 2006 May;74(5):3039-41. doi: 10.1128/IAI.74.5.3039-3041.2006.
Infect Immun. 2006.
PMID: 16622247
Free PMC article.
We have previously shown that vaccination with a vaccine based on the recombinant N-terminal domain of Als1p (rAls1p-N) protected BALB/c mice against disseminated infection caused by a single strain of Candida albicans (A. S. Ibrahim, B. J. Spellberg, V. Avenissian, …
We have previously shown that vaccination with a vaccine based on the recombinant N-terminal domain of Als1p (rAls1p-N) protected BALB/c mic …